MaxCyte, Inc. Notice of Half Year Results (9391O)
August 25 2017 - 2:00AM
UK Regulatory
TIDMMXCT TIDMMXCR
RNS Number : 9391O
MaxCyte, Inc.
25 August 2017
MaxCyte, Inc.
("MaxCyte" or the "Company")
Notice of Half Year Results
Maryland, USA - 25 August 2017: MaxCyte (LSE: MXCT, MXCR), a
US-based global company driving the acceleration of the discovery,
development, manufacturing and commercialization of
next-generation, cell-based medicines, will announce its interim
results for the six months ended 30 June 2017 on Tuesday 19
September 2017.
Doug Doerfler, Chief Executive Officer, will host a presentation
and live conference call for analysts at 11:00 BST on the day of
the results at the offices of Panmure Gordon, 1 New Change, London
EC4M 9AF.
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive
Officer
Ron Holtz, Chief Financial
Officer +1 301 944 1660
Nominated Adviser and Broker
Panmure Gordon
Freddy Crossley (Corporate
Finance)
Duncan Monteith
Ryan McCarthy
Tom Salvesen (Corporate Broking) +44 (0) 20 7886 2500
Financial PR Adviser
Consilium Strategic Communications
Mary-Jane Elliott +44 (0)203 709 5700
Chris Welsh maxcyte@consilium-comms.com
Lindsey Neville
About MaxCyte
MaxCyte (LSE: MXCT, MXCR) is a US-based global company driving
the acceleration of the discovery, development, manufacturing and
commercialization of next-generation, cell-based medicines. The
Company provides its patented, high-performance cell engineering
platform to biopharmaceutical partners engaged in drug discovery
and development, biomanufacturing, and cell therapy, including gene
editing and immuno-oncology. With its robust delivery platform,
MaxCyte's team of scientific experts helps its partners to unlock
their product potential and solve problems. This platform allows
for the engineering of nearly all cell types, including human
primary cells, with any molecule, at any scale. It also provides a
high degree of consistency and minimal cell disturbance, thereby
facilitating rapid, large-scale, clinical and commercial grade cell
engineering in a non-viral system and with low-toxicity concerns.
The Company's cell-engineering platform is FDA-accredited,
providing MaxCyte's customers and partners with an established
regulatory path to commercialize cell-based medicines.
MaxCyte is also developing CARMA, its proprietary, breakthrough
platform in immuno-oncology, to rapidly manufacture CAR therapies
for a broad range of cancer indications, including solid tumors
where existing CAR-T approaches face significant challenges.
For more information, visit http://www.maxcyte.com/
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORPIMITMBTTBIR
(END) Dow Jones Newswires
August 25, 2017 02:00 ET (06:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024